Spotlight

News

esteller davalos merkel villasante

Dos pájaros de un tiro: un análisis bioinformático mejorado puede estimar las variaciones del número de copias genéticas a partir de datos epigenéticos

Un equipo liderado por el Dr. Manel Esteller, director del Instituto de Investigación contra la Leucemia Josep Carreras, ha mejorado la identificación computacional de amplificaciones de genes medicables en tumores, a partir de datos epigenéticos. Mediante esta nueva herramienta, los científicos pueden tener información fiable sobre los datos moleculares de un tumor en particular tanto a nivel genético como epigenético, incluso cuando la muestra es escasa.

Leer más
Visita Ministra Diana Morant

El Instituto de Investigación contra la Leucemia Josep Carreras es seleccionado por el Instituto Nacional del Cáncer de Estados Unidos para el proyecto Proteoma del Cáncer, con el apoyo del Ministerio de Ciencia e Innovación

El Instituto Josep Carreras entra a formar parte del proyecto Proteoma del Cáncer, una iniciativa internacional para el estudio de los tumores malignos. Cuenta con el apoyo del Ministerio de Ciencia e Innovación, cuya Ministra, Diana Morant, visitó el jueves el Instituto Josep Carreras y anunció una ayuda de un millón de euros para impulsar el proyecto. 

Leer más
Grup Briones - Sant Pau

Finaliza la Fase I del primer ensayo clínico CAR-T30 de Europa, de producción propia, para linfoma de Hodgkin y no-Hodgkin T

El primer ensayo con un medicamento de inmunoterapia CAR-T producido en San Pablo, pionero en Europa, para el tratamiento del linfoma de Hodgkin clásico y linfoma no-Hodgkin T CD30+ en recidiva o refractario, ha finalizado su Fase I con éxito . El proyecto está liderado por el dr. Javier Briones, jefe de la Unidad de Hematología Clínica del Servicio de Hematología del Hospital de Sant Pau y jefe del Grupo de investigación de Inmunoterapia Celular y Terapia Génica del Instituto de Investigación del Hospital de Sant Pau - IIB-Sant Pau y el Instituto de Investigación contra la Leucemia Josep Carreras.

Leer más

Un análisis de sangre permite distinguir si unos síntomas son causados por la COVID-19 grave o por la preeclampsia en mujeres embarazadas

El equipo de investigación dirigido por Marta Palomo, del Instituto de Investigación contra la Leucemia Josep Carreras, y Fátima Crispi, de BCNatal-IDIBAPS, ha identificado marcadores que permiten diferenciarlas. Estos resultados, enmarcados en un proyecto financiado por La Marató de TV3, abren la puerta a un diagnóstico más preciso de estas enfermedades, y a una mejor evaluación del riesgo.

Leer más
Genescà i Solé

Eulàlia Genescà y Francesc Solé: “Estamos haciendo pasos reales hacia la implementación de lo que llamamos medicina personalizada”

Las herramientas de diagnóstico de la leucemia que la investigación básica pone a disposición de los clínicos no dejan de aumentar y las nuevas tecnologías de secuenciación genómica e inteligencia artificial están penetrando en un mundo dominado, hasta hace poco, por metodologías clásicas basadas en la observación microscópica directa y los marcadores analíticos.

Leer más

El Instituto de Investigación contra la Leucemia Josep Carreras, nuevo miembro de CataloniaBio & HealthTech

Esta colaboración permitirá al Instituto de Investigación contra la Leucemia Josep Carreras posicionarse como entidad referente en el sector de la biomedicina y la investigación. Se pretende potenciar los ejes estratégicos comunes como cooperación empresarial, modelos de negocio en digital health, acceso a los mercados internacionales, transferencia de tecnología y captación de inversión.

Leer más

Últimas publicaciones

Blecua P, Davalos V, de Villasante I, Merkel A, Musulen E, Coll-SanMartin L, Esteller M

Refinement of computational identification of somatic copy number alterations using DNA methylation microarrays illustrated in cancers of unknown primary.

Brief Bioinform 6 May 2022, . Epub 6 May 2022
High-throughput genomic technologies are increasingly used in personalized cancer medicine. However, computational tools to maximize the use of scarce tissues combining distinct molecular layers are needed. Here we present a refined strategy, based on the R-package 'conumee', to better predict somatic copy number alterations (SCNA) from deoxyribonucleic acid (DNA) methylation arrays. Our approach, termed hereafter as 'conumee-KCN', improves SCNA prediction by incorporating tumor purity and dynamic thresholding. We trained our algorithm using paired DNA methylation and SNP Array 6.0 data from The Cancer Genome Atlas samples and confirmed its performance in cancer cell lines. Most importantly, the application of our approach in cancers of unknown primary identified amplified potentially actionable targets that were experimentally validated by Fluorescence in situ hybridization and immunostaining, reaching 100% specificity and 93.3% sensitivity.
Más información
Garcia-Prieto CA, Martínez-Jiménez F, Valencia A, Porta-Pardo E

Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.

Bioinformatics 5 May 2022, . Epub 5 May 2022
The analysis of cancer genomes provides fundamental information about its aetiology, the processes driving cell transformation or potential treatments. While researchers and clinicians are often only interested in the identification of oncogenic mutations, actionable variants or mutational signatures, the first crucial step in the analysis of any tumor genome is the identification of somatic variants in cancer cells (i.e., those that have been acquired during their evolution). For that purpose, a wide range of computational tools have been developed in recent years to detect somatic mutations in sequencing data from tumor samples. While there have been some efforts to benchmark somatic variant calling tools and strategies, the extent to which variant calling decisions impact the results of downstream analyses of tumor genomes remains unknown.
Más información
Arribas AJ, Napoli S, Cascione L, Sartori G, Barnabei L, Gaudio E, Tarantelli C, Mensah AA, Spriano F, Zucchetto A, Rossi FM, Rinaldi A, De Moura MC, Jovic S, Bordone-Pittau R, Di Veroli A, Stathis A, Cruciani G, Stussi G, Gattei V, Brown JR, Esteller M, Zucca E, Rossi D, Bertoni F

Resistance to PI3κδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis.

Haematologica 28 Abr 2022, . Epub 28 Abr 2022
PI3KPPinhibitors are active in patients with lymphoid neoplasms and a first series of them have been approved for the treatment of multiple types of B-cell lymphoid tumors, including marginal zone lymphoma (MZL). The identification of the mechanisms underlying either primary or secondary resistance is fundamental to optimize the use of novel drugs. Here, we present a model of secondary resistance to PI3Kffinhibitors obtained by prolonged exposure of a splenic MZL cell line to idelalisib. The VL51 cell line was kept under continuous exposure to idelalisib. The study included detailed characterization of the model, pharmacological screens, silencing experiments, validation experiments on multiple cell lines and on clinical specimens. VL51 developed resistance to idelalisib, copanlisib, duvelisib, and umbralisib. An integrative analysis of transcriptome and methylation underlined an enrichment of up-regulated transcripts and lowmethylated promoters in resistant cells, including IL-6/STAT3 and PDGFRA related genes and surface CD19 expression, alongside the repression of the let-7 family miRNAs, of miR-125, miR-130, miR-193 and miR-20. The use of the IL-6R blocking antibody tocilizumab, the STAT3 inhibitor stattic, the LIN28 inhibitor LIN1632, the PDGFR inhibitor masitinib and the anti-CD19 antibody drug conjugate loncastuximab tesirine were active compounds in the resistant cells as single agents and/or in combination with PI3K//inhibition. Findings were validated on additional in vitro lymphoma models and on clinical specimens. A novel model of resistance obtained from splenic MZL allowed the identification of therapeutic approaches able to improve the anti-tumor activity of PI3Kttinhibitors in B-cell lymphoid tumors.
Más información
Cao X, Li W, Wang T, Ran D, Davalos V, Planas-Serra L, Pujol A, Esteller M, Wang X, Yu H

Accelerated biological aging in COVID-19 patients.

Nat Commun 19 Abr 2022, 13 (1) 2135. Epub 19 Abr 2022
Chronological age is a risk factor for SARS-CoV-2 infection and severe COVID-19. Previous findings indicate that epigenetic age could be altered in viral infection. However, the epigenetic aging in COVID-19 has not been well studied. In this study, DNA methylation of the blood samples from 232 healthy individuals and 413 COVID-19 patients is profiled using EPIC methylation array. Epigenetic ages of each individual are determined by applying epigenetic clocks and telomere length estimator to the methylation profile of the individual. Epigenetic age acceleration is calculated and compared between groups. We observe strong correlations between the epigenetic clocks and individual's chronological age (r > 0.8, p < 0.0001). We also find the increasing acceleration of epigenetic aging and telomere attrition in the sequential blood samples from healthy individuals and infected patients developing non-severe and severe COVID-19. In addition, the longitudinal DNA methylation profiling analysis find that the accumulation of epigenetic aging from COVID-19 syndrome could be partly reversed at late clinic phases in some patients. In conclusion, accelerated epigenetic aging is associated with the risk of SARS-CoV-2 infection and developing severe COVID-19. In addition, the accumulation of epigenetic aging from COVID-19 may contribute to the post-COVID-19 syndrome among survivors.
Más información
Ferrer G, Álvarez-Errico D, Esteller M

Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer.

J Natl Cancer Inst 19 Abr 2022, . Epub 19 Abr 2022
Adoptive cell therapy (ACT) constitutes a major breakthrough in cancer management that has expanded in the past years due to impressive results showing durable and even curative responses for some patients with hematological malignancies. ACT leverages antigen specificity and cytotoxic mechanisms of the immune system, particularly relying on the patient´s T lymphocytes to target and eliminate malignant cells. This personalized therapeutic approach exemplifies the success of the joint effort of basic, translational and clinical researchers that has turned the patient´s immune system into a great ally in the search for a cancer cure. Adoptive cell therapies are constantly improving to reach a maximum beneficial clinical response. Despite being very promising therapeutic options for certain types of cancers, mainly melanoma and hematological malignancies, these individualized treatments still present several shortcomings including elevated costs, technical challenges, management of adverse side effects and a limited population of responder patients. Thus, it is crucial to discover and develop reliable and robust biomarkers to specifically and sensitively pinpoint the patients that will benefit the most from ACT, as well as those that are at higher risk of developing potentially serious toxicities. Although unique readouts of infused cell therapy success have not yet been identified, certain characteristics from the adoptive cells, the tumor and/or the tumor microenvironment have been recognized to predict patients' outcome upon ACT. Here, we comment on the importance of biomarkers to predict ACT chances of success to maximize efficacy of treatments and increase patients' survival.
Más información

Agenda